Go to Top

VEXIM IN BRIEF

  • Profil

  • SpineJack®

  • Masterflow

  • Capital structure

  • Governance

  • Scientific committee

Vexim, the innovative micro surgery of the back

Based in Balma, near Toulouse (France), Vexim is a medical device specialist created in February 2006 following its spinoff from Teknimed, a world leader in bone substitutes and surgical cements. Vexim is specialized in the design and marketing of minimally invasive solutions for the treatment of traumatic spinal pathologies. The company benefits from the financial support of its shareholders, Truffle Capital, BPI, Banexi Ventures Partners and Foord Global Equity Fund.

Vexim markets the SpineJack®, a unique implant capable of repairing a deformed or fractured vertebra and restoring the anatomy of the spinal column. Vexim has also developed the Masterflow™, a unique solution for mixing and injecting orthopedic cement that enhances accuracy and optimizes the surgical procedure. The company currently has 60 employees, as well as its own sales teams in France, Germany, Italy, Spain and the United Kingdom. Since September 2014, Vexim initiated activities in the US market. The company is also marketing SpineJack® in others part of the world through specialized distributors.

SpineJack®, a revolutionary implant for the treatment of vertebral fractures

spine-solution

The revolutionary nature of SpineJack® resides in its ability to restore a fractured vertebra to its original shape, as well as the optimal anatomy of the spinal column, thereby enabling the patient to recover his functional abilities and neutralizing pain. Thanks to state-of-the-art tools, implantation within the vertebra is minimally invasive, X-ray guided and takes less than 30 minutes, so the patient can return home shortly after the procedure. The SpineJack® range is composed of three implants of three different diameters, made of titanium, therefore applicable to 95% of vertebral compression fractures and all types of patient morphology.
The SpineJack® technology benefits from the support of international scientific experts in the field of spinal columns and worldwide patent protection through to 2029.

spine-solution

Masterflow system is redefining cement delivery in vertebral augmentation. It is a unique solution for mixing and injecting orthopedic cement that enhances accuracy and optimizes the surgical procedure. Masterflow was launched in the US in February 2015 and got the CE Approval to Market in Europe in March 2015.


Mastering your
Procedural Experience

capital-en

Organization Chart (executives)

  • Chief Executive Officer

    Vincent Gardès holds a Bachelor of Arts in Business Administration from INSEEC Business School and a Post-Graduate Certificate in Leadership Capability from Glasgow Caledonian University. He speaks three languages (French, English and Spanish). Vincent Gardès began his career in 1995 at Stryker Spine as Product Manager for Europe. From 1996 to 1999, he held the position of Sales & Marketing Manager Knees & Spine at the Spanish subsidiary, Stryker Spain. Returning to France in 1999, he successively held the positions of Team Leader Hips for Stryker Europe, then Global Group Product Manager for Stryker Spine until 2002. At the end of 2002, Vincent Gardès joined the Medtronic Group, where he held the position of Spine Division Director for Europe. In 2004, he was promoted to Business Unit Manager Spine & Biologics, France, then in 2007, to Business Director for Southern Europe. Since September 2008, Vincent Gardès was CEO of CR Bard for Spain and Portugal, based in Barcelona. Starting in July 2011, he consulted for Vexim on behalf of Truffle Capital. Vincent Gardès was appointed Chief Executive Officer of Vexim in December 2011.

  • Vice President and US General Manager

    Russell brings more than 25 years of Medical Device experience in both the U.S. and International markets. Prior to VEXIM, Russell has served in various leadership roles with both NuVasive and Medtronic. Most recently Russell held the position of Executive Vice President of International and President of China for NuVasive. Prior to that, he served as Senior Vice President, Operations and Senior Vice President of Spinal and Biologics at NuVasive. During his 13 year-career at Medtronic, Russell held the positions of Vice President, U.S. Sales Operations, Vice President, International and various positions in Global Marketing. Russell began his career in orthopaedics and spine with Smith & Nephew as a member of the Trauma Marketing Group. Russell received a B.B.A from the University of Memphis.

  • Chief Financial Officer & Executive Director

    José Da Gloria is a university graduate of Versailles with a Master’s degree in Economy and Finance. Before joining Vexim as Chief Financial Officer in March 2014, he participated in the launch of a French start-up of cloud computing: Cloudwatt as head of Finance. José was, from 2010 till 2013, Financial controller of a $250 million International division at ev3, a US medical device company acquired in 2010 by Covidien, specialized in the vascular implants. He participated in the business development in the emerging countries (Latin America and Asia) as well as the financial, logistic and fiscal integration of the ev3 entities inside Covidien. Further to this integration, he integrated Covidien as the EMEA FP&A Director, a €2.5 billion Revenue. From 2008 till 2010, he was Finance Planning and Analysis manager and then Finance controller for the international division of ev3. He began his career in 2000 in the IT industry as FP&A analyst and took various finance and leadership roles inside Dell inc.

  • VP Europe

    With over 13 years of experience in the Healthcare Industry, he started working as a sales rep for Sandoz (Novartis Generics) moving to a territory manager function until making the transition into Medical devices in 2007, when he started helping Spinal Kinetics, with their Artificial Disc Replacement technology enter the OUS markets. He was co-responsible for commercializing their products and building the business in all major markets with great success, all the way up to reaching the critical milestone of 25,000 implants achieved in app. 6years of time. Since 2013, he accepted a new challenge when he joined R&D start-up, Orthobion GmbH, in Germany. Orthobion was a developer of innovative interbody fusion implants, that were treated with a specialized surface and coating procedure. He was responsible for product-development, working closely with key EU surgeons alike, and setting a pathway for the company’s first commercial successes in the EMEA region. He graduated a Master in International Business Management at the Vlerick Business School, in Louvain/ Ghent, in partnership with London Business School, as well as other shorter term executive courses in Sales and Marketing. Gunther has extensive experience in Business development, Sales, Clinical education, Marketing, as well as Regulatory and Clinical, where he will help provide benefit to our Organization at Vexim.

  • VP International & Marketing

    Sebastien joins Vexim from Tornier where he was Vice President for Large Joints, one of the three global business units of the company. During his tenure at Tornier he was responsible for the Hip & Knee business, accounting for 40m€ in sales. With his team he crafted and executed a successful strategy in more than 30 countries in collaboration with affiliates and distributors. His biggest success came in 2014 driving revenues up 10% in a flat market. Sebastien also served on corporate committees such as the Intellectual Property Board, Grants & Donations committee and Corporate Compliance Committee.
    Prior to this role Sebastien was Business Unit Director Spine at Zimmer France. There he executed the integration following the acquisition of the Abbott Spine portfolio, and grew the business from €2.5m to €5m in two years. Before this assignment he was Director of Marketing at Zimmer France. Earlier Sebastien had a 10-year career at Stryker in various roles including R&D, European Marketing and Business Development. Sebastien brings a 19-year successful experience at both strategic and operational levels. He is graduated in mechanical engineering and also holds a Master’s degree in Business Administration.

  • VP Operations

    François Cathelineau starts his career in 2001 in the Aluminum industry, working for Pechiney. He then enters the automotive industry, as a manufacturing manager. He joins GE Healthcare in 2005, and will hold different positions with increasing responsibilities in process, quality and operations management within the manufacturing division. He becomes France installation manager in 2011, looking after the whole Healthcare product portfolio. In 2014, he joins the global service supply chain leadership team as EMEA supply chain manager, supporting a $1.4Bn business.
    François Cathelineau brings a 15-year successful experience in operations management & product development, in several industries and international environment. He graduated from Ecole MinesParisTech and Sciences-Po Paris.

Members of the Board of Directors

  • Chairman

    Steve Swinson holds a PhD in electrical engineering from Manchester University in the United Kingdom and an MBA from the University of Chicago. Prior to joining Vexim’s board Steve Swinson was responsible for leading the Spine & Biologics business for Western Europe and Canada at Medtronic. He was previously International Vice President for Spine & Biologics. Previously at Medtronic, he was Vice President for Emerging Markets responsible for P&L and operating margins for all Medtronic product lines, covering a wide geography from South Asia including India, Africa, Middle East and Latin America. Steve Swinson has over 30 years’ experience in international business. He managed the indirect channel of distributors for Hewlett Packard Medical Products Group in Europe and was Vice President of Marquette Medical Systems for Asia Pacific. He also managed the Diagnostic X-ray business on global basis for GE Medical Systems in 2002.

  • Chief Executive Officer

    Vincent Gardès holds a Bachelor of Arts in Business Administration from INSEEC Business School and a Post-Graduate Certificate in Leadership Capability from Glasgow Caledonian University. He speaks three languages (French, English and Spanish). Vincent Gardès began his career in 1995 at Stryker Spine as Product Manager for Europe. From 1996 to 1999, he held the position of Sales & Marketing Manager Knees & Spine at the Spanish subsidiary, Stryker Spain. Returning to France in 1999, he successively held the positions of Team Leader Hips for Stryker Europe, then Global Group Product Manager for Stryker Spine until 2002. At the end of 2002, Vincent Gardès joined the Medtronic Group, where he held the position of Spine Division Director for Europe. In 2004, he was promoted to Business Unit Manager Spine & Biologics, France, then in 2007, to Business Director for Southern Europe. Since September 2008, Vincent Gardès was CEO of CR Bard for Spain and Portugal, based in Barcelona. Starting in July 2011, he consulted for Vexim on behalf of Truffle Capital. Vincent Gardès was appointed Chief Executive Officer of Vexim in December 2011.

  • Truffle Capital representative

    Philippe Pouletty is a Doctor of Medicine (Université Paris VI), immunologist, former intern with the Hospitals of Paris, a laureate of the Pasteur Institute (immunology) and a postdoctoral fellow at Stanford University. He is the inventor of 29 patents, including the second-most profitable for Stanford University, in life sciences. Philippe Pouletty is the Founder and Managing Director of Truffle Capital, a fund with 500 million euros of equity under management. He was the President of France Biotech, the French association of biotechnology companies, and former Vice-President of EuropaBio, the European association for bio-industries. He also founded three biotech companies in Europe and the United States, which generated market capitalization of over 800 million dollars, and is a member of the board of 12 biotech and medical device companies in Europe and North America (BMD, Carmat, Deinove, Innate Pharma, ITS, Neovacs, Pharnext, PlasmaPrime, Splicos, Symetis, Theraclion, Vexim and Wittycell). Philippe Pouletty was also responsible for several governmental initiatives in France, including the 1999 law that simplified company law (SAS), the “Plan Biotech 2002” to launch and develop biotechnology, and the Jeune Entreprise Innovante (Young Innovative Enterprise) status, which awards significant tax exemptions to tech companies.

  • Strategic Consultant for SKEMA Business School

    Bernard Belloc holds a Ph.D. in Economic Sciences, a post-graduate doctorate in mathematical economics and econometrics, and a post-graduate professorial degree (“aggregation”) in law and economic sciences. He started his career as a professor at the Université de Bordeaux 1, then taught at the Université de Toulouse 1, which he presided between 1998 and 2003. A member of the French national council for universities (CNU) from 1992 to 1998, he was also a member of the board of Edufrance (2000-2001) and Vice-Chairman of the French university presidents conference (CPU) from 2000 to 2002. From 1990 to 1993, he was a member of various experts groups for the Ministry of Higher Education studying contracts with institutions. In 2002-2003, he was entrusted by Minister Luc Ferry with proposing a reform of the university professor and associate professor status. In parallel, Bernard Belloc was appointed to the Conseil économique et social Midi-Pyrénées (2002), the Haut comité éducation-économie-emploi (2001-2004) and a number of other councils and committees, including the Haut conseil de la coopération internationale (HCCI). In the 2000s, he joined a number of international missions in the United States and Asia. Bernard Belloc was a science and technology advisor for the French Embassy in China from 2005 to 2007. He was then appointed Advisor on Higher Education and Research by the French President. Since September 2012, he has held the position of Strategic Consultant for the SKEMA Business School.

  • Pharmacist and ESSEC graduate

    Antoine Pau started his career at Novartis Pharma in the Business Planning Analysis department (Oncology Business Unit). He then joined Mazars as financial auditor where he worked for three years managing the legal audits of pharmaceutical and biotech companies, as well as investments funds, and also participated in the financial due diligence process for tech companies in the Transaction Services department. He joined Truffle Capital in 2008, where he holds the position of Life Sciences Investment Director. He is also a lecturer at Science Po in Paris.

  • Chief of Services, Clinical Radiology of Oklahoma

    Dr. Douglas P. Beall attended medical school at Georgetown University and completed his residency at The Johns Hopkins Hospital. Following completion of his residency, he was chief of interventional services at Sheppard Air Force Base. He then completed a fellowship in musculoskeletal radiology at the Mayo Clinic in Rochester, MN, where he was trained in joint and spine injection techniques before returning to the U.S. Air Force where he was division chief of the musculoskeletal section. In addition to his expertise in musculoskeletal imaging and interventional spine care, Dr. Beall is a diplomate of the American Academy of Pain and is actively involved in teaching and research. Dr. Beall has published more than 180 articles in peer-reviewed journals, has authored three textbooks and 11 textbook chapters and has given more than 200 invited lectures and scientific presentations.

  • CEO of Acteon Group

    Mrs. Marie-Laure Pochon has been Chief Executive Officer of the Acteon Group, since October 2014. From 2007 to 2012, she worked in Lundbeck where she notably served as Chief Executive of Lundbeck France; Regional Vice President for Western Europe and also Chief Operating Officer (Executive VP for Commercial Operations) for the whole Lundbeck Group. From 2012 to 2013, she was working with GN Store Nord where she was Senior Vice-President for Europe & Strategic Accounts. Marie-Laure Pochon worked during 30 years in the Pharmaceutical Industry, where she started in large US groups: MSD during 12 years and then Pfizer during 4 years. After this first period, she was appointed Managing Director in Schwarz Pharma (8 years) and then in Lundbeck (6 years). She served as an Executive Director in Lundbeck; as a Director in Mauna Kea Technologies SAS from June 2012 to June 2014 and was also part of the Leem Board during 6 years. Besides, she co-founded an association of pharmaceuticals companies (CRIP). By education, she holds an Engineer degree (ESPCI, Physics & Chemistry Paris) and a MBA for HEC Paris.

Scientific Committee

Dr.Antonio-Kruger

Dr. Antonio KRÜGER

Germany

Senior Physician, Trauma & Reconstructive Surgery

Head of Department: Prof. Dr. S.Ruchholtz

Marburg University

Prof.David-Noriega

Prof. David NORIEGA

Spain

Orthopedic Surgeon

University Hospital

Valladolid

Dr.Gianluca-Maestretti

Dr. Gianluca MAESTRETTI

Switzerland

Spinal Surgery

Orthopedics, Fribourg Cantonal Hospital

Dr-RENAUD-Christian

Dr. Christian RENAUD

France

Orthopedic Surgeon

Toulouse / Albi Clinic

Honorary member

Faculty Members

Dr.Frank-HasselDr. Frank Hassel

Orthopedic Surgeon

 

Dr.Harald-KuhnDr. Harald Kuhn

Orthopedic Surgeon

 

Dr.Jörg-BeyerleinDr. Jörg Beyerlein

Orthopedic Surgeon

 

Dr.Ludovic-RillardonDr. Ludovic Rillardon

Orthopedic Surgeon

 

 

Prof. Nicolas Theumann
Prof. Nicolas Theumann

Interventional Radiologist

 

Dr.Robert-Rotter
Dr. Robert Rotter

Orthopedic Surgeon

 

Dr.Francisco-Ardura
Dr. Francisco Ardura

Orthopedic Surgeon

 

Dr.Helmut Ekkerlein
Dr H. Ekkerlein

Orthopedic Surgeon

 

Dr.Guizzardi-GiancarloDr. Guizzardi Giancarlo

Neurosurgeon